Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis

Open Access 12-04-2024 | Cytostatic Therapy | Research

Microarray-based detection and expression analysis of drug resistance in an animal model of peritoneal metastasis from colon cancer

Authors: Vugar Yagublu, Bayram Bayramov, Christoph Reissfelder, Javahir Hajibabazade, Shalala Abdulrahimli, Michael Keese

Published in: Clinical & Experimental Metastasis

Login to get access

Abstract

Chemotherapy drugs efficiently eradicate rapidly dividing differentiated cells by inducing cell death, but poorly target slowly dividing cells, including cancer stem cells and dormant cancer cells, in the later course of treatment. Prolonged exposure to chemotherapy results in a decrease in the proportion of apoptotic cells in the tumour mass. To investigate and characterize the molecular basis of this phenomenon, microarray-based expression analysis was performed to compare tHcred2-DEVD-EGFP-caspase 3-sensor transfected C-26 tumour cells that were harvested after engraftment into mice treated with or without 5-FU. Peritoneal metastasis was induced by intraperitoneal injection of C-26 cells, which were subsequently reisolated from omental metastatic tumours after the mice were sacrificed by the end of the 10th day after tumour injection. The purity of reisolated tHcred2-DEVD-EGFP-caspase 3-sensor-expressing C-26 cells was confirmed using FLIM, and total RNA was extracted for gene expression profiling. The validation of relative transcript levels was carried out via real-time semiquantitative RT‒PCR assays. Our results demonstrated that chemotherapy induced the differential expression of mediators of cancer cell dormancy and cell survival-related genes and downregulation of both intrinsic and extrinsic apoptotic signalling pathways. Despite the fact that some differentially expressed genes, such as BMP7 and Prss11, have not been thoroughly studied in the context of chemoresistance thus far, they might be potential candidates for future studies on overcoming drug resistance.
Literature
1.
Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 68(6):394–424CrossRef
2.
Mutch MG (2016) The Surgical Management of Colon Cancer. The ASCRS textbook of colon and rectal surgery. Springer, Berlin, pp 443–470CrossRef
3.
Vogel JD et al (2017) The American society of colon and rectal surgeons clinical practice guidelines for the treatment of colon cancer. Dis Colon Rectum 60(10):999–1017PubMedCrossRef
4.
Meyers BM et al (2016) Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline. Curr Oncol 23(6):418–424PubMedPubMedCentralCrossRef
5.
6.
Pan ST et al (2016) Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol 43(8):723–737PubMedCrossRef
7.
8.
9.
Maji S et al (2018) Bcl-2 antiapoptotic family proteins and chemoresistance in cancer. Advances in cancer research. Elsevier, Amsterdam, pp 37–75
10.
Huang Z et al (2016) Stress management by autophagy: implications for chemoresistance. Int J Cancer 139(1):23–32PubMedCrossRef
11.
Oh JH, Deasy JO (2016) A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer. Brief Bioinform 17(3):468–478PubMedCrossRef
12.
Talukdar S et al (2019) Dormancy and cancer stem cells: an enigma for cancer therapeutic targeting. Elsevier, Amsterdam, pp 43–84CrossRef
13.
Gimenez-Bonafe P, Tortosa A, Perez-Tomas R (2009) Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets 9(3):320–340PubMedCrossRef
14.
Longley DB, Johnston PG (2005)  Molecular mechanisms of drug resistance. J Pathol 205(2):275–292PubMedCrossRef
15.
Fujita K et al (2017) Cancer therapy due to apoptosis: galectin-9. Int J Mol Sci 18:1CrossRef
16.
Keese M et al (2010) Fluorescence lifetime imaging microscopy of chemotherapy-induced apoptosis resistance in a syngenic mouse tumor model. Int J Cancer 126(1):104–113PubMedCrossRef
17.
Crea F et al (2015) The epigenetic/noncoding origin of tumor dormancy. Trends Mol Med 21(4):206–211PubMedCrossRef
18.
Lin W-J, Hsueh H-M, Chen JJ (2010) Power and sample size estimation in microarray studies. BMC Bioinform 11(1):1–9CrossRef
19.
Tibshirani R (2006) A simple method for assessing sample sizes in microarray experiments. BMC Bioinform 7:1–6CrossRef
20.
Linde N, Fluegen G, Aguirre-Ghiso J (2016) The relationship between dormant cancer cells and their microenvironment. Elsevier, Amsterdam, pp 45–71
21.
22.
Kischkel FC et al (1995) Cytotoxicity-dependent APO‐1 (Fas/CD95)‐associated proteins form a death‐inducing signaling complex (DISC) with the receptor. EMBO J 14(22):5579–5588PubMedPubMedCentralCrossRef
23.
Li H et al (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94(4):491–501PubMedCrossRef
24.
25.
26.
27.
28.
Levy-Strumpf N, Kimchi A (1998) Death associated proteins (DAPs): from gene identification to the analysis of their apoptotic and tumor suppressive functions. Oncogene 17(25):3331–3340PubMedCrossRef
29.
Lamkanfi M, Kanneganti T-D (2010) Caspase-7: a protease involved in apoptosis and inflammation. Int J Biochem Cell Biol 42(1):21–24PubMedCrossRef
30.
Zheng H et al (2013) Fas signaling promotes motility and metastasis through epithelial–mesenchymal transition in gastrointestinal cancer. Oncogene 32(9):1183–1192PubMedCrossRef
31.
32.
Yuan J et al (2020) The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol 13(1):1–19CrossRef
33.
Xie Y et al (2019) PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia. Mol Med Rep 19(2):783–791PubMed
34.
Hers I, Vincent EE, Tavaré JM (2011) Akt signalling in health and disease. Cell Signal 23(10):1515–1527PubMedCrossRef
35.
Steelman LS et al (2008) Akt as a therapeutic target in cancer. Expert Opin Ther Targets 12(9):1139–1165PubMedCrossRef
36.
37.
McCubrey JA et al (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46(1):249–279PubMedCrossRef
38.
39.
40.
41.
Veschi V et al (2020) Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant. Oncogene 39(5):987–1003PubMedCrossRef
42.
43.
Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti-and pro-angiogenic therapies. Genes cancer 2(12):1097–1105PubMedPubMedCentralCrossRef
44.
45.
Cong R et al (2006) Hhex is a direct repressor of endothelial cell-specific molecule 1 (ESM-1). Biochem Biophys Res Commun 346(2):535–545PubMedCrossRef
46.
Kang YH et al (2012) ESM-1 regulates cell growth and metastatic process through activation of NF-κB in colorectal cancer. Cell Signal 24(10):1940–1949PubMedCrossRef
47.
Kolev V et al (2008) EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol 10(8):902–911PubMedPubMedCentralCrossRef
48.
49.
Liu Z-J et al (2003) Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 23(1):14–25PubMedPubMedCentralCrossRef
50.
51.
Baldi A et al (2002) The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene 21(43):6684–6688PubMedCrossRef
52.
53.
Zhu F et al (2010) Serine protease HtrA1 expression in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 9(5):508–512PubMed
54.
55.
Catalano V et al (2011) HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer. Histopathology 58(5):669–678PubMedCrossRef
Metadata
Title
Microarray-based detection and expression analysis of drug resistance in an animal model of peritoneal metastasis from colon cancer
Authors
Vugar Yagublu
Bayram Bayramov
Christoph Reissfelder
Javahir Hajibabazade
Shalala Abdulrahimli
Michael Keese
Publication date
12-04-2024
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-024-10283-5
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits